The presence of nodal metastases in patients with prostate cancer is a key factor determining prognosis and treatment. With the reintroduction of ferumoxtran-10-enhanced MRI in local clinical practice, small metastases in lymph nodes down to 2 mm in size can be detected non-invasively, avoiding diagnostic surgical lymph node dissections and guiding personalized treatment of patients with prostate cancer at intermediate and high risk for metastatic spread.
This abstract and the presentation materials are available to members only; a login is required.